Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
Oncotarget
; 7(35): 57301-57309, 2016 Aug 30.
Article
in En
| MEDLINE
| ID: mdl-27359058
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Drug Administration Schedule
/
Antineoplastic Agents, Hormonal
/
Estrogen Receptor alpha
/
Estradiol
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
Oncotarget
Year:
2016
Document type:
Article
Affiliation country:
China